FEMY Stock Overview A biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Femasys Historical stock prices Current Share Price US$1.18 52 Week High US$2.40 52 Week Low US$0.86 Beta -2.81 1 Month Change 8.26% 3 Month Change 4.42% 1 Year Change -2.48% 3 Year Change -59.31% 5 Year Change n/a Change since IPO -90.17%
Recent News & Updates
Femasys Announces Israeli Regulatory Approvals for Femaseed® for Female Infertility Treatment and Two Diagnostic Devices Feb 04
Femasys Inc. Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control Jan 30
Femasys Inc. Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment Jan 16
Femasys Inc. Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemSeed® Infertility Treatment Nov 26
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 14
Consensus revenue estimates fall by 17% Nov 13 See more updates
Femasys Announces Israeli Regulatory Approvals for Femaseed® for Female Infertility Treatment and Two Diagnostic Devices Feb 04
Femasys Inc. Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control Jan 30
Femasys Inc. Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment Jan 16
Femasys Inc. Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemSeed® Infertility Treatment Nov 26
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 14
Consensus revenue estimates fall by 17% Nov 13
Femasys (NASDAQ:FEMY) Has Debt But No Earnings; Should You Worry? Oct 31
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec, an Innovative Diagnostic Solution for Fallopian Tube Check Sep 11
Consensus revenue estimates fall by 40% Aug 15
New major risk - Financial position Aug 11
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 09
Shareholders May Be More Conservative With Femasys Inc.'s (NASDAQ:FEMY) CEO Compensation For Now Jul 05
Femasys Inc., Annual General Meeting, Jul 12, 2024 Jun 10
Consensus revenue estimates decrease by 17%, EPS upgraded May 16
Price target increased by 8.1% to US$10.00 May 12
New major risk - Financial position May 10
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 10
Consensus revenue estimates fall by 13% Apr 04
Health Check: How Prudently Does Femasys (NASDAQ:FEMY) Use Debt? Apr 03
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 31
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution Mar 07
New major risk - Share price stability Feb 09
Femasys Inc. Appoints Richard Spector as Chief Commercial Officer Feb 06
Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At UC Davis Medical Center, A Hub for Innovation and Groundbreaking Research in Health Care for Women Jan 26
Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At University of Utah Jan 23
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine Dec 15 Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors Nov 23
Femasys Inc. Appoints Joshua Silverman as Director Nov 22
New major risk - Shareholder dilution Nov 19
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 17
Consensus revenue estimates fall by 11% Nov 16
New major risk - Revenue and earnings growth Nov 16
Femasys Inc. Successfully Completes the Stage 2 European Union (EU) Medical Device Regulation Oct 29
Here's Why We're Watching Femasys' (NASDAQ:FEMY) Cash Burn Situation Sep 27 Femasys Inc. Obtains Medical Device Establishment License from Health Canada Sep 01
New major risk - Revenue and earnings growth Aug 12
Femasys Inc. Designates Daniel Currie as its Chief Operating Officer Aug 11
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 11
Femasys Inc. Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, A Non-Surgical Alternative for Women Jun 28
Femasys Inc. Announces Management Changes Jun 16
Femasys' FemCath Intrauterine Catheter Receives Product Approval in Canada Jun 09
Femasys Receives a Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement Jun 03
Consensus EPS estimates upgraded to US$0.93 loss, revenue downgraded May 18
Femasys Inc., Annual General Meeting, Jun 21, 2023 May 16
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind May 12
Femasys Inc.'s FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada May 05
Consensus EPS estimates fall by 32% Apr 06
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 31
Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device Dec 20
Femasys Inc. Reports Encouraging Promotional Launch of Femcerv At AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons Dec 13
Femasys Inc. Completes Over 25% of its Targeted Enrollment in its FemaSeed De Novo Trial Nov 30
Price target decreased to US$7.33 Nov 16
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 11
Femasys Inc. Provides Strategic Update on FemaSeed Pivotal Trial Design to Expedite Clinical Program Advancement Oct 21
Femasys Inc. Appoints Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs, Effective October 10, 2022 Oct 13
Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control Oct 07
Femasys Inc. Announces Commercial Availability of FemCerv® Sep 30
Femasys commercially launches Femcerv for cervical cancer screening Sep 29
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 12
Femasys GAAP EPS of -$0.22 beats by $0.01, revenue of $0.3M misses by $0.01M Aug 10
Femasys Inc. Announces Board Changes Jul 07
We Think Femasys (NASDAQ:FEMY) Needs To Drive Business Growth Carefully May 22
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 13
Femasys Inc. Appoints Dov Elefant to Chief Financial Officer, Effective February 28, 2022 Feb 25
Insufficient new directors Jan 01
Femasys: Revolutionizing Female Reproduction Jul 16
Independent Director recently bought US$172k worth of stock Jun 28
Femasys Inc. has completed an IPO in the amount of $34.45 million. Jun 19 Shareholder Returns FEMY US Medical Equipment US Market 7D 0% -0.9% 0.2% 1Y -2.5% 12.5% 22.0%
See full shareholder returns
Return vs Market: FEMY underperformed the US Market which returned 22% over the past year.
Price Volatility Is FEMY's price volatile compared to industry and market? FEMY volatility FEMY Average Weekly Movement 9.0% Medical Equipment Industry Average Movement 8.8% Market Average Movement 6.1% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.1%
Stable Share Price: FEMY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: FEMY's weekly volatility (9%) has been stable over the past year.
About the Company Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing.
Show more Femasys Inc. Fundamentals Summary How do Femasys's earnings and revenue compare to its market cap? FEMY fundamental statistics Market cap US$27.02m Earnings (TTM ) -US$18.10m Revenue (TTM ) US$1.26m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) FEMY income statement (TTM ) Revenue US$1.26m Cost of Revenue US$430.79k Gross Profit US$829.85k Other Expenses US$18.93m Earnings -US$18.10m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.79 Gross Margin 65.83% Net Profit Margin -1,436.04% Debt/Equity Ratio 84.9%
How did FEMY perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/07 02:39 End of Day Share Price 2025/02/07 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Femasys Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Keay Nakae Chardan Capital Markets, LLC Emily Bodnar H.C. Wainwright & Co. Catherine Novack JonesTrading Institutional Services, LLC
Show 1 more analysts 
